Claims

1. Use of mesenchymal stem cells expressing HLA-A2 on a surface thereof in the manufacture of a medicament for the prevention or treatment of an inflammatory disease, wherein the mesenchymal stem cells express HLA-A2 at a level that is higher than mesenchymal stem cells not expressing HLA-A2 by 70% or more, wherein the mesenchymal stem cells are derived from umbilical cord blood, and wherein the mesenchymal stem cells increase the expression of CD163 and Arg-1.

2. The use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 1 wherein on the surface thereof, the mesenchymal stem cells express any one selected from the group consisting of CD73, CD90, CD105, CD166, and combinations thereof, and do not express any one selected from the group consisting of CD14, CD34, CD45, HLA-DR, and combinations thereof.

3. The use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 1 wherein on the surface thereof, the mesenchymal stem cells express each of CD73, CD90, CD105, and CD166 at a level that is higher than mesenchymal stem cells not expressing HLA-A2 by 70% or more, and express each of CD14, CD34, CD45, and HLA-DR at a level that is lower than mesenchymal stem cells not expressing HLA-A2 by 1% or less.

4. The use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 2 wherein on the surface thereof, the mesenchymal stem cells express HLA-A2 at a level that is higher than mesenchymal stem cells not expressing HLA-A2 by 75% or more, express each of CD73, CD90, CD105, and CD166 at a level that is higher than mesenchymal stem cells not expressing HLA-A2 by 70% or more, and express each of CD14, CD34, CD45, and HLA-DR at a level that is lower than mesenchymal stem cells not expressing HLA-A2 by of 1% or less.

5. The use of mesenchymal stem cells expressing HLA-A2 on a surface thereof as claimed in claim 1 wherein the inflammatory disease is rheumatoid arthritis, atopy, asthma, allergic rhinitis, Alzheimer's disease, graft versus host disease (GVHD), diabetic nephropathy, Crohn's disease, inflammatory bowel disease, rejection after transplantation, bronchopulmonary dysplasia (BPD), or chronic obstructive pulmonary disease (COPD).